Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jennifer Berry

Nurse Practitioner, Family Albany, GA Nurse Practitioner

NPI 1447489117 CMS profile 10681765

105 Spanish Ct, Albany, GA 31707

Open in the dashboard

General payments

$15,767

518 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jennifer Berry of Albany, GA is reported in the CMS Open Payments database as having received $15,767 across 518 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,856 156
2024 General $2,382 98
2023 General $2,485 103
2022 General $2,487 93
2021 General $1,557 68

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennifer Berry
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Jennifer Berry were reported at $6,856. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Jennifer Berry Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,557 $124 $35–$379 $132
2022 $2,487 $141 $44–$430 $149
2023 $2,485 $154 $49–$476 $160
2024 $2,382 $165 $51–$504 $164
2025 $6,856 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. CSL Behring $4,224 40 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $1,628 54 payments
  3. GlaxoSmithKline, LLC. $1,476 88 payments
  4. AstraZeneca Pharmaceuticals LP $1,374 49 payments
  5. Regeneron Healthcare Solutions, Inc. $1,364 51 payments
  6. AbbVie, Inc. $810 28 payments
  7. Genzyme Corporation $726 19 payments
  8. BioCryst US Sales Co., LLC $642 25 payments
  9. Grifols USA, LLC $624 32 payments
  10. Pfizer Inc. $559 35 payments
  11. Other $2,341 97 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $12,041 512 payments
  2. Consulting Fee $3,101 3 payments
  3. Travel and Lodging $570 2 payments
  4. Education $56 1 payment
Products named General payments · program years 2021–2025
  1. Hizentra $4,027 32 payments
  2. Privigen $3,521 9 payments
  3. TRELEGY ELLIPTA $1,025 68 payments
  4. DUPIXENT Inflammation And Immunology $1,020 42 payments
  5. DUPIXENT Immunology $910 28 payments
  6. CUVITRU $867 41 payments
  7. RINVOQ $709 29 payments
  8. Orladeyo $642 25 payments
  9. GLASSIA $634 7 payments
  10. FASENRA $628 21 payments
  11. Other $6,834 290 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

1,302

Median for Nurse Practitioner: 389

Drug cost

$162,490

Median for Nurse Practitioner: $21,885

Branded share of claims

24%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Syringe Dupilumab Brand 12 $46,307
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 48 $34,801
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 38 $30,124
Breo Ellipta Fluticasone/Vilanterol Brand 17 $12,393
Xhance Fluticasone Propionate Brand 14 $12,180
Symbicort Budesonide/Formoterol Fumarate Brand 18 $6,323
Azelastine Hcl Generic 146 $4,587
Arnuity Ellipta Fluticasone Furoate Brand 13 $3,641
Fluticasone Propionate Generic 214 $2,910
Albuterol Sulfate Hfa Albuterol Sulfate Brand 98 $2,440

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $262
  • GENZYME CORPORATION $143
$405 12 —
RINVOQ
  • AbbVie, Inc. $271
$271 — —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $122
  • Amgen Inc. $97
$219 — —
CUVITRU
  • Takeda Pharmaceuticals U.S.A., Inc. $177
$177 — —
Orladeyo
  • BioCryst US Sales Co., LLC $173
$173 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

518 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record